Screening for prostate cancer in african americans

Current Urology Reports

Volumn 1, Issue 1, 2000, Pages 57-64

  Moul, Judd W ^a  

^a Center for Prostate Disease Research   (United States)

Author keywords

Curable Prostate Cancer; Early Detection Effort; Prostate Cancer; Prostate Cancer Screening; Radical Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ATTITUDE TO HEALTH; BLOOD; HUMAN; MALE; MASS SCREENING; NEGRO; PROSTATE TUMOR; REVIEW; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 0034191149     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-000-0036-y     Document Type: Article

References (64)

1. Boring CC, Squires TS, Health CW: Cancer statistics for African Americans. CA Cancer J Clin 1993, 43:7–17.
2. Kosary CL, Ries LAG, Miller BA, et al.: SEER cancer statistics review, 1973–1992: table and graphs. National Cancer Institute. National Institutes of Health Pub. No. 96-2789, 1995.
3. Morton, RA, Racial differences in adenocarcinoma of the prostate in North American men. Urology 1994, 44:637–645. DOI: 10.1016/S0090-4295(94)80196-7
4. Aronson WJ, Freeland ST: Editorial: Can we lower the mortality of black men with prostate cancer? J Urol 2000, 163:150–151. Important study. DOI: 10.1016/S0022-5347(05)67992-X
5. Cooper R, David R: The biologic concept of race and the application to public health and epidemiology. J Health Polit Policy Law 1986, 11:97–116.
6. Osborne NG, Feit MD: The use of race in medical research. JAMA 1992, 267:275–279. DOI: 10.1001/jama.267.2.275
7. Witzig R: The medicalization of race: scientific legitimization of a flawed social construct. Ann Intern Med 1996, 125:675–679.
8. Brawley OW, Freeman HP: Race and outcomes: Is this the end of the beginning for minority health research? JNCI 1999, 91:1908–1909. DOI: 10.1093/jnci/91.22.1908
9. Robinson SB, Ashley M, and Haynes MA: Attitudes of African Americans regarding screening for prostate cancer. J Natl Med Assoc 1996, 88:241–246.
10. Robinson SB, Ashley M, Haynes MA: Attitudes of African Americans regarding prostate cancer clinical trials. J Community Health 1996, 21:77–87. DOI: 10.1007/BF01682300
11. Abbott RR, Taylor DK, Barber K: A comparison of prostate knowledge of African American and Caucasian men: changes from prescreening baseline to post intervention. Cancer J Sci Am 1998, 4:175–177.
12. Bennett CL, Ferreira MR, Davis TC, et al.: Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol 1998, 16:3101–3104.
13. Guidry JJ, Fagan P, Walker V: Cultural sensitivity and readability of breast and prostate printed cancer education materials targeting African Americans. J Nat Med Assoc 1998, 90:165–169.
14. Myers RE, Chodak GW, Wolf TA, et al.: Adherence by African American men to prostate cancer education and early detection. Cancer 1999, 86:88–104. DOI: 10.1002/(SICI)1097-0142(19990701)86:1<88::AID-CNCR14>3.0.CO;2-D
15. Weinrich SP, Boyd MD, Weinrich M, et al.: Increasing prostate cancer screening in African American men with peer-educator and client-navigator interventions. J Cancer Educ 1998, 13:213–129.
16. Powell IJ, Heilbrun L, Littrup P, et al.: Outcomes of African American men screened for prostate cancer. The Detroit Education and Early Detection study. J Urol 1998, 158:146–149. DOI: 10.1097/00005392-199707000-00045
17. Moul JW: Editorial comment to outcomes of African American men screened for prostate cancer: The Detroit Education and Early Detection Study. J Urol 1997, 158:149. DOI: 10.1016/S0022-5347(01)64146-6
18. Mouton CP: Special health considerations in African-American elders. Am Family Physician 1997, 55:1243–1253.
19. McCoy-Sibley RI, Sibley AF: Correlation of digital rectal examination, prostate specific antigen, and transrectal ultrasound in prostate carcinoma in African Americans. J Natl Med Assoc 1997, 89:318–323.
20. Woolf SH, Screening for prostate cancer with prostatespecific antigen. An examination of the evidence. N Engl J Med 1995, 333:1401–1405. DOI: 10.1056/NEJM199511233332107
21. Barry MJ, Robert RG: Indications for PSA testing. JAMA 1997, 277:955. DOI: 10.1001/jama.277.12.955
22. American College of Physicians. Screening for Prostate Cancer. Ann Intern Med 1997, 126:480-484.
23. Von Eschenbach A, Ho R, Murphy GP, et al.: American Cancer Society guidelines for the early detection of prostate cancer. Cancer 1997, 80:1805–1807. DOI: 10.1002/(SICI)1097-0142(19971101)80:9<1805::AID-CNCR17>3.0.CO;2-9
24. Hankey BF, Feuer EJ, Clegg LX, et al.: Cancer surveillance series: Interpreting trends in prostate cancer-Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999, 91:1017–1024. DOI: 10.1093/jnci/91.12.1017
25. Etzioni R, Legler JM, Feuer EJ, et al.: Cancer surveillance series: Interpreting trends in prostate cancer-Part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999, 91:1033–1039. DOI: 10.1093/jnci/91.12.1033
26. Labrie F, Candas B, Dupont A, et al.: Screening decreases prostate cancer death: First analysis of the 1998 Quebec prospective randomized controlled trial. Prostate 1999, 38(2):83–91. DOI: 10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B
27. Roach J, Won M, Keller J, Perez CA, et al.: The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group Protocols (1976-1985). Int J Radiat Oncol Bio Phys 1992, 24:441–449.
28. Optenberg SA, Thompson IM, Friedrichs P, et al.: Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA 1995, 274:1599. DOI: 10.1001/jama.274.20.1599
29. Eastham JA, Kattani MW: Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol 2000, 163:143–145. Key study. DOI: 10.1016/S0022-5347(05)67990-6
30. Powell IJ, Banerjee M, Sakr W, et al.: Should African American men be tested for prostate carcinoma at an earlier age than white men? Cancer 1999, 85:472–477. DOI: 10.1002/(SICI)1097-0142(19990115)85:2<472::AID-CNCR27>3.0.CO;2-0
31. Vijayakumar S, Karrison T, Weichselbaum RR, et al.: Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidermiol Biomarkers Prev 1992, 1:541–545.
32. Staggers FM, DeAntoni EP, Crawford ED, et al.: A profile of African-American participants in Prostate Cancer Awareness Week (PCAW) 1992. J Urol 1994, 151:291(A255).
33. Bullock A, Smith DS, Basler J, et al.: Racial differences in prostate cancer detection and staging. J Urol 1994, 151:291(A#57).
34. Moul JW, Sesterhenn IA, Connelly RR, et al.: Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. J Am Med Assoc 1995, 274:1277–1281. DOI: 10.1001/jama.274.16.1277
35. Vijayakumar S, Weichselbaum RR, Vaida F, et al.: Prostate specific antigen levels in African Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J Sci Am 1996, 2:225–233.
36. Abdalla I, Ray P, Ray V, et al.: Comparison of serum prostatespecific antigen levels and PSA density in African American, white, and Hispanic men without prostate cancer. Urology 1998, 51:300–305. DOI: 10.1016/S0090-4295(97)00617-1
37. Abdalla I, Ray P, Vaida F, Vijayakumar S: Racial differences in prostate-specific antigen levels and prostate specific antigen densities in patients with prostate cancer. Am J Clin Oncol 1999, 22:537–541. DOI: 10.1097/00000421-199912000-00001
38. Vijayakumar S, Winter K, Sause W, et al.: Prostate specific antigen levels are higher in African Americans than in white patients in a multicenter registration study: results of RTOG 94-12. Int J Radiat Oncol Biol Phys 1998, 40:17–25. DOI: 10.1016/S0360-3016(97)00834-1
39. Vijayakumar S, Vaida F, Weichselbaum RR, Hellman S: Race and the Will Rogers phenomenon in prostate cancer. Cancer J Sci Am 1998, 4:27–34.
40. Moul JW, Connelly RR, Mooneyhan RM, et al.: Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol 1999, 162:394–397. An important study. DOI: 10.1016/S0022-5347(05)68568-0
41. Zhang W, Sesterhenn IA, Connelly RR, et al.: Inflammatory infiltrate (prostatitis) in whole-mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference prostate-specific antigen. J Urol 2000, 163:131–136. DOI: 10.1016/S0022-5347(05)67988-8
42. Eastman JA, May RA, Whatley T, et al.: Clinical characteristics and biopsy specimen features in African American and white men without prostate cancer. J Natl Cancer Inst 1998, 90:756–760. DOI: 10.1093/jnci/90.10.756
43. Sakr WA, Grignon DJ, Haas GP, et al.: Epidemiology of high-grade intraepithelial neoplasia. Pathol Res Pract 1995, 191:838–841.
44. Sakr WA, Wheeler TM, Blute M, et al.: International consultation on prostatic intraepithelial neoplasia and pathologic staging of prostatic carcinoma: staging and reporting of prostate cancer sampling of the radical prostatectomy specimen. Cancer 1996, 78:366–368. DOI: 10.1002/(SICI)1097-0142(19960715)78:2<366::AID-CNCR29>3.0.CO;2-T
45. Ross RK, Bernstein L, Lobo RA, et al.: 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Cancer 1992, 339:887.
46. Irvine RA, Ross RK, Coetzee GA: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995, 55:1937–1940.
47. Smith DS, Bullock AD, Catalona WJ, Herschan JD: Racial differences in a prostate cancer screening study. J Urol 1996, 156:1366–69. DOI: 10.1016/S0022-5347(01)65588-5
48. Smith DS, Bullock AD, Catalona WJ: Racial differences in operating characteristics of prostate cancer screening tests. J Urol 1997, 58:1861–1866. DOI: 10.1016/S0022-5347(01)64147-8
49. Smith DS, Carvalhal GF, Mager DE, et al.: Use of lower prostate-specific antigen cut-offs for prostate cancer screening in black and white men. J Urol 1998, 160:1734–1738. DOI: 10.1016/S0022-5347(01)62395-4
50. Morgan TO, Jacobson SJ, McCarthy WF, et al.: Age-specific reference ranges for prostate-specific antigen in black men. New Engl J Med 1996, 335:304–310. DOI: 10.1056/NEJM199608013350502
51. Oesterling JE, Jacobson ST, Cjite CG, et al.: Serum prostatespecific antigen in a community-based population of healthy men. JAMA 1993, 270:860–864. DOI: 10.1001/jama.270.7.860
52. Littrup PJ: Prostate cancer in African-American men [editorial]. 1997, 31:139–141.
53. Littrup PJ, Sparschu RA: Transrectal ultrasound and prostate cancer risks: The “tailored” prostate biopsy. Cancer 1995, 75(suppl):1805–1813. DOI: 10.1002/1097-0142(19950401)75:7+<1805::AID-CNCR2820751609>3.0.CO;2-K
54. Powell IJ, Banerjee M, Novallo M, et al.: Should the age-specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years? J Urol 2000, 163:146–149. DOI: 10.1016/S0022-5347(05)67991-8
55. Moul JW: Curability of prostate cancer in African Americans: Implications for Neoadjuvant/Adjuvant hormonal therapy. Mol Urol 1998, 2:209.
56. Moul JW: PSA thresholds for prostate cancer detection. JAMA 1997, 278:699. DOI: 10.1001/jama.278.9.699b
57. Carter HB, et al.: Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997, 277:1456–1460. DOI: 10.1001/jama.277.18.1456
58. Catalona WJ: Screening for prostate cancer [letter]. N Eng J Med 1996, 334:666–667. DOI: 10.1056/NEJM199603073341016
59. Bullock AD, Harmon T, Smith DS, Basler JW: Prostate cancer screening in younger men [abstract]. J Urol 1997, S66:157.
60. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ngmL and benign prostate examination. JAMA 1997, 277:1452–1455. DOI: 10.1001/jama.277.18.1452
61. Preston DM, Levin LI, Jacobson, et al.: Prostate specific antigen levels in young Caucasian and African American men age 20–45. Urology 2000, in press.
62. Moul JW, Connelly RR, Barko WF, Vaitkus M: Should healthy Caucasian men between the age of 40–49 be screened for prostate cancer: a Department of Defense (DoD) Center for Prostate Disease Research (CPDR) and Army Physical Fitness Research Institute (APFRI) prospective study at the U.S. Army War College (USAWC). J Urol 2000, 163(suppl 4):90, abstract #393.
63. Hartzell J, Kao C, Moul JW: Age-adjusted prostate-specific antigen (PSA) in men between 30–59 years of age: National Defense University study. Publication pending.
64. Moul JW: A PSA cutoff of 4 is too high for many men. Contemp Urol 1999, 11:15–32.